Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_assertion type Assertion NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_head.
- NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_assertion description "[Here, we explore the therapeutic potential of dasatinib, a small-molecule inhibitor that targets multiple cytosolic and membrane-bound tyrosine kinases, including members of the Src kinase family, EphA2, and focal adhesion kinase for the treatment of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_provenance.
- NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_assertion evidence source_evidence_literature NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_provenance.
- NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_assertion SIO_000772 19861960 NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_provenance.
- NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_assertion wasDerivedFrom befree-20140225 NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_provenance.
- NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_assertion wasGeneratedBy ECO_0000203 NP789854.RAGU_u_DU_htcX1oN-OCxHcIIIANH8gksE8o9dnSpgX2E130_provenance.